课题基金 / 基金详情

Development of a novel biomaterial model of collagen mediated genetic disease for study of collagen organisation and drug development

Development of a novel biomaterial model of collagen mediated genetic disease for study of collagen organisation and drug development
开发胶原蛋白介导的遗传病的新型生物材料模型,用于研究胶原蛋白组织和药物开发
批准号:
2897511
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Osteogenesis imperfecta (OI) is a group of 17 inherited connective tissue disorders mediated by mutations in collagen genes that lead to bone deformation and fragility. Currently, in vivo testing is the standard practice for treatments, with over 20 animal models representing OI. These models are technically limited, but also with regards to accessibility and reproducibility of collagen alignment and organisation. A validated in vitro method would allow for accurate preclinical modelling.Mesenchymal stem cells (MSC) can differentiate into bone forming cells and create a bone-like collagen extracellular matrix. Work in Prof. Reilly's group has demonstrated that the organisation and quality of the collagen can be modelled in a tissue specific manner. We propose that the genetic mutations that cause OI will also affect the ability of cells to organise collagen correctly, and that using this scaffold-cell system will provide important insight into OI pathogenesis. The aim of this project is to develop characterised and validated in vitro model of OI collagen pathology. This will be achieved by using electo-spinning to produce polycaprolactone scaffolds on which cells will be grown following established protocols. The relationship between scaffold fibre characteristics and collagen structure will be mapped using light microscopy and SEM for scaffold characteristics, and histology and second harmonic generation microscopy for cellular and extracellular factors. Mechanical testing will be used to determine the role of collagen organisation in tissue structure. OI mutations identified from patient populations will be introduced to MSC cells using CRISPR endogenous gene editing enabling comparison between healthy vs OI collagen. This will allow for investigation of the molecular pathways and testing of therapeutic agents. A high throughput image analysis protocol using ImageJ will be developed for systematic analysis of large data sets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: